Drug profile · INN
anileridine hydrochloride
LERITINE
anileridine hydrochloride (LERITINE) is a kappa opioid receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — anileridine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
anileridine hydrochloride (LERITINE) is a kappa opioid receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Kappa opioid receptor agonist
Primary target: Kappa-type opioid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is anileridine hydrochloride?
anileridine hydrochloride (LERITINE) is a kappa opioid receptor agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for anileridine hydrochloride?
LERITINE is a marketed brand name for anileridine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of anileridine hydrochloride?
anileridine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.